SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk - PACE-CME

SGLT inhibition in the management of type diabetes Potential impact on CVD Risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

MinuteCE®
Optimizing care for patients with CKM syndrome: a multidisciplinary approach
1.00 credit 4 episodes
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Jürgen Floege, MD
- Muthiah Vaduganathan, MD, MPH
1.00 credit 4 episodes
Screening for CKM syndrome
Screening for CKM syndrome
MinuteCE®
Screening for CKM syndrome
1.00 program credit
- Jürgen Floege, MD
1.00 program credit
Disease-modifying effects of finerenone in CKM syndrome
Disease-modifying effects of finerenone in CKM syndrome
ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
- Muthiah Vaduganathan, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD